On 14 April 2026 the Dominican Republic joined the Global Fund list of countries introducing lenacapavir for prevention, alongside eleven others. Access, which was the question, now has an answer. The next one is harder: a twice yearly injection requires knowing who received a dose and when the next one is due.
Almost everything written about lenacapavir is about access: who is inside the licenses and who is left out. That is a legitimate discussion and it is well covered. This piece is about what happens next, which is far less covered and is where it gets decided whether the medicine does any good.
What changed in April 2026?
On 14 April 2026 the Global Fund announced it was extending support for introducing lenacapavir as pre-exposure prophylaxis to twelve further countries, the Dominican Republic among them. With the nine early rollout countries that makes twenty-one, and the stated ambition is to reach three million people through 2028.
The contrast is worth seeing, because it explains why the public conversation has gone elsewhere. The United States price is around 28,000 dollars per person per year. Published estimates put the cost of manufacturing a generic between 25 and 40 dollars. And several middle income countries were left outside the voluntary licenses, including Brazil, Argentina, Mexico and Peru, which are precisely the countries that hosted the clinical trial showing the drug works.
The Dominican Republic is not in that group. It is inside. Which is why its operational question differs from its neighbors.
Why is a twice yearly injectable a different problem?
Because it changes the unit that has to be tracked. A daily pill is dispensed against an inventory and an adherence the patient manages. An injection every six months makes the follow up the product: if nobody knows this person is due in November, the dose is not given, and a dose missed is not half protection, it is an interruption.
That requires a longitudinal record per person: who received what, when, and when they return. It is a different shape of information from the one epidemiological surveillance moves today, which is aggregate and weekly. Both are necessary and they are not interchangeable.
What does the country already have?
More than tends to be assumed, and that is worth saying before proposing anything.
There is a working web notification platform. There are forty provincial and area health directorates publishing indicators every week. There is an institutional habit of measuring coverage and timeliness and comparing them across territories, which is the hardest part to build and the part already built.
What is not designed for this is the shape of the data. The weekly channel answers the question how many cases there were this week in this territory. A six monthly prophylaxis program needs to answer who is due next month and where they live, which does not follow from the first.
What would need solving, in what order?
Three things, and the first is not technological:
- Decide who is responsible for following each person when six months pass between contacts. A system does not replace a responsible person; it only tells them who to call.
- Decide how the same person is identified across two visits half a year apart, including the possibility that the second happens at a different facility or in a different province. It is the decision that constrains everything else.
- Define the indicator before building anything. For a six monthly prophylaxis, the measure that matters is what share of due doses were given inside the window. If that number cannot be calculated, the program cannot be steered.
And the part that does not depend on the country?
Supply and price are not settled from Santo Domingo, and pretending otherwise would be dishonest. What is decided here is whether, on the day the doses arrive, there is a way to know whose they are.
That preparation has a rarely discussed advantage: it can be done in advance, and it can be assessed on its own. Nobody has to wait for a first dose to find out whether the system can recall a person six months out.
What this analysis does not claim
It does not claim the Dominican Republic is unprepared. It claims the readiness question is a different one from the access question, and that the first has had far less public attention than the second.
It evaluates no particular Dominican program, because doing so would need data that is not public.
And it takes no position on the voluntary licenses or on the price. Others do that with more authority and better data.
Sources
Global Fund release of 14 April 2026 on the expanded commitment to lenacapavir introduction, which carries the list of the twelve added countries and the three million people through 2028 ambition. United States price and generic manufacturing cost estimates: published literature on lenacapavir pricing and patents. Exclusion of Brazil, Argentina, Mexico and Peru from the voluntary licenses despite having hosted the PURPOSE-2 trial: public analyzes by medicines access organizations.
- Epidemiological surveillance
- Policy and regulation
- District-level reporting